Bifidobacterium bifidum is a Gram-positive, anaerobic bacterium that is neither motile nor spore-forming. The bacterium is rod-shaped and can be found living in clusters, pairs, or even independently. It was isolated from baby feces.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
CAT | Size | Price | Quantity | |
---|---|---|---|---|
LBST-049FG |
|
Product Information | |
---|---|
Product Overview | Bifidobacterium bifidum is a Gram-positive, anaerobic bacterium that is neither motile nor spore-forming. The bacterium is rod-shaped and can be found living in clusters, pairs, or even independently. It was isolated from baby feces. |
Target | Bifidobacterium |
Genus | Bifidobacterium |
Strain Designation | VPI 11241[Ti] |
Application | Study and research |
Type Strain | Yes |
Culture Medium | BBL |
Culture Conditions | 37°C; Anaerobic |
Source | Baby feces |
Characteristics | Gram-positive, the cells are rod-shaped. Solitary, paired, v-shaped or stacked, no buds. Strictly anaerobic, it ferments glucose to produce lactic acid. |
Risk Group | 1 |
Product Format | Freeze-dried |
Packaging | Ampoule tube |
Storage | -80°C |
Shelf Life | 6 years |
Target Introduction | |
---|---|
Introduction | Bifidobacterium are Gram-positive, heterofermentative, anaerobic bacteria with a distinctive bifid; i.e. Y shape after which they are named. They are originally isolated from the faeces of breast-fed infants, members of the genus Bifidobacterium are commonly found in the GI tract of mammals. In humans, Bifidobacterium resides within the GI tract, from birth to old age. Disturbances in the microbiota are linked to an ever-growing number of immune-linked disease states including IBD, atopic allergy, arthritis, and obesity. Therefore, there is a significant interest in treating these diseases through microbial or "probiotic" supplementation of patients, including Bifidobacterium. Data from mouse models and clinical trials indicate that Bifidobacterium may have beneficial effects for treating and preventing immune-linked diseases, including gut-associated and systemic conditions. Bifidobacterium have been commercially exploited as probiotic agents due to their associated health benefits and GRAS; Generally Recognised As Safe status. |
Alternative Names | Bifidobacterium bifidum; Baby feces |
Bifidobacterium bifidum can be preserved in cryoprotective agents like glycerol at temperatures below -80°C. This method ensures viability and stability over extended periods, maintaining its probiotic properties intact.
Viability can be assessed using standard microbiological methods such as plate counting (CFU/mL), spectrophotometric measurements of optical density, and viability staining techniques like LIVE/DEAD assays. These methods ensure accurate quantification of viable cells before and after experimental treatments.
Bifidobacterium bifidum thrives in anaerobic conditions with a growth medium containing carbohydrates like glucose and fructose, supplemented with appropriate nitrogen sources such as peptones and yeast extract. These conditions support optimal growth and metabolic activity.
In vitro assessments include testing acid and bile tolerance, adhesion capabilities to intestinal epithelial cells, and production of bioactive metabolites like short-chain fatty acids. These assays provide insights into its potential as a probiotic strain for gastrointestinal health applications.
Standardization of experimental protocols, including growth conditions, inoculum preparation, and assay procedures, is crucial for reproducibility. Calibration of equipment and periodic validation of culture purity and viability contribute to reliable outcomes across diverse research studies.
Relationship between xylooligosaccharide (XOS) doses or fractions and its bifidogenic activity
The study examines the role of Bifidobacterium bifidum; 29521 in gastrointestinal health, highlighting its impact on gut microbiota composition and functionality. Experimental findings underscore its ability to enhance intestinal barrier function by promoting mucin production and modulating immune responses. Moreover, studies demonstrate its efficacy in reducing inflammation markers such as interleukin-6 and tumor necrosis factor-alpha, crucial in mitigating conditions like inflammatory bowel disease. Furthermore, Bifidobacterium bifidum; 29521 shows promise in improving nutrient absorption, particularly in enhancing the bioavailability of vitamins and minerals. These outcomes underscore its potential therapeutic value in managing digestive disorders and supporting overall gastrointestinal well-being. The research underscores the significance of utilizing Bifidobacterium bifidum; 29521 as a probiotic intervention to optimize gut health through targeted modulation of gut microbiota and immune function, emphasizing its potential application in clinical settings for enhancing digestive health outcomes.
Sun, Zhongke, et al. "Assessment of the bifidogenic and antibacterial activities of xylooligosaccharide." Frontiers in Nutrition 9 (2022): 858949. Distributed under Open Access license CC BY 4.0, without modification.
Click the button below to contact us or submit your feedback about this product.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Copyright © 2024 Creative Biolabs. All Rights Reserved.